サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1109367

加齢黄斑変性症（AMD）の北米市場 - 業界動向と2029年までの予測

NA Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 116 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
加齢黄斑変性症（AMD）の北米市場 - 業界動向と2029年までの予測
出版日: 2022年05月01日
発行: Data Bridge Market Research
ページ情報: 英文 116 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の加齢黄斑変性症（AMD）の市場規模は、2022年～2029年の予測期間にCAGRで8.0%の成長が予測されています。高齢者人口の増加や、黄斑変性症の流行が、市場の成長に寄与しています。

当レポートでは、北米の加齢黄斑変性症（AMD）市場について調査分析し、業界動向や予測、セグメント分析、企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL
  • ポーターのファイブフォースモデル

第5章 規制の枠組み

第6章 市場の概要

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第7章 北米の加齢黄斑変性症（AMD）市場：タイプ別

  • 概要
  • ドライ型AMD
  • ウェット型AMD

第8章 北米の加齢黄斑変性症（AMD）市場：エンドユーザー別

  • 概要
  • 病院
  • 専門診療所
  • 外来手術センター
  • 在宅医療
  • その他

第9章 北米の加齢黄斑変性症（AMD）市場：流通チャネル別

  • 概要
  • 小売
    • 病院薬局
    • 小売薬局
    • その他
  • 直接販売

第10章 北米の加齢黄斑変性症（AMD）市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ

第11章 北米の加齢黄斑変性症（AMD）市場：企業情勢

  • 企業シェア分析：北米

第12章 SWOT分析

第13章 企業プロファイル

  • NOVARTIS AG
  • GENENTECH, INC.
  • BAYER AG
  • ADVERUM BIOTECHNOLOGIES, INC.
  • ASTELLAS PHARMA INC.
  • GRAYBUG VISION INC.
  • GENSIGHT BIOLOGICS
  • IONIS PHARMACEUTICALS
  • IVERIC BIO
  • JOHNSON &JOHNSON SERVICES, INC.
  • KODIAK SCIENCES INC.
  • MEIRAGTX LIMITED
  • OCUGEN INC.
  • PIXIUM VISION
  • REGENXBIO INC.

第14章 アンケート

第15章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION 37
  • TABLE 2 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 51
  • TABLE 3 NORTH AMERICA DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 52
  • TABLE 4 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 53
  • TABLE 5 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 53
  • TABLE 6 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 54
  • TABLE 7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION) 58
  • TABLE 8 NORTH AMERICA HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 59
  • TABLE 9 NORTH AMERICA SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 60
  • TABLE 10 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 61
  • TABLE 11 NORTH AMERICA HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 62
  • TABLE 12 NORTH AMERICA OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 62
  • TABLE 13 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION) 67
  • TABLE 14 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 68
  • TABLE 15 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 68
  • TABLE 16 NORTH AMERICA DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION) 69
  • TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 75
  • TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 75
  • TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 75
  • TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 75
  • TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION) 75
  • TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 76
  • TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 76
  • TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 77
  • TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 77
  • TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 77
  • TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION) 77
  • TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 78
  • TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 78
  • TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 79
  • TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 79
  • TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 79
  • TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION) 79
  • TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 80
  • TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL,, 2020-2029 (USD MILLION) 80
  • TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 81
  • TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 81
  • TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION) 81
  • TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION) 81
  • TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 82
  • TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 82

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION 18
  • FIGURE 2 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION 21
  • FIGURE 3 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS 22
  • FIGURE 4 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 23
  • FIGURE 5 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS 23
  • FIGURE 6 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING 24
  • FIGURE 7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS 25
  • FIGURE 8 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID 26
  • FIGURE 9 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID 27
  • FIGURE 10 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS 28
  • FIGURE 11 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION 31
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 32
  • FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 33
  • FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029 33
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 40
  • FIGURE 16 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021 49
  • FIGURE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION) 50
  • FIGURE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029) 50
  • FIGURE 19 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE 51
  • FIGURE 20 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021 56
  • FIGURE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION) 57
  • FIGURE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029) 57
  • FIGURE 23 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE 58
  • FIGURE 24 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021 65
  • FIGURE 25 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 66
  • FIGURE 26 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 66
  • FIGURE 27 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 67
  • FIGURE 28 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : SNAPSHOT (2021) 72
  • FIGURE 29 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY COUNTRY (2021) 73
  • FIGURE 30 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY COUNTRY (2022 & 2029) 73
  • FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY COUNTRY (2021 & 2029) 74
  • FIGURE 32 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY TYPE (2022-2029) 74
  • FIGURE 33 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%) 83
目次

North-America age-related macular degeneration (AMD) market is projected to register a CAGR of 8.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

North-America Age-Related Macular Degeneration (AMD) Market, By Types (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others) and Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the North-America age-related macular degeneration (AMD) market are:

Growing geriatric population

Growing prevalence of macular degeneration

Market Players:

The key market players for North-America age- related macular degeneration (AMD) market are listed below:

Novartis AG

Bayer AG

REGENXBIO Inc.

Ionis Pharmaceutics

Ocugen Inc

Johnson & Johnson Services, Inc

IVERIC bio

MeiraGTx Limited

Adverum Biotechnologies, Inc.

Graybug Vision Inc.

Kodiak Sciences Inc.

Genentech Inc.

TABLE OF CONTENTS

1 INTRODUCTION 13

  • 1.1 OBJECTIVES OF THE STUDY 13
  • 1.2 MARKET DEFINITION 13
  • 1.3 OVERVIEW OF NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 13
  • 1.4 LIMITATIONS 15
  • 1.5 MARKETS COVERED 15

2 MARKET SEGMENTATION 18

  • 2.1 MARKETS COVERED 18
  • 2.2 GEOGRAPHICAL SCOPE 19
  • 2.3 YEARS CONSIDERED FOR THE STUDY 20
  • 2.4 CURRENCY AND PRICING 20
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
  • 2.6 MULTIVARIATE MODELLING 24
  • 2.7 TYPE LIFELINE CURVE 24
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
  • 2.9 DBMR MARKET POSITION GRID 26
  • 2.10 MARKET END USER COVERAGE GRID 27
  • 2.11 VENDOR SHARE ANALYSIS 28
  • 2.12 SECONDARY SOURCES 29
  • 2.13 ASSUMPTIONS 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 33

  • 4.1 PESTEL 34
  • 4.2 PORTER'S FIVE FORCES MODEL 35

5 REGULATORY FRAMEWORK 36

6 MARKET OVERVIEW 39

  • 6.1 DRIVERS 41
    • 6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 41
    • 6.1.2 INCREASING GERIATRIC POPULATION 41
    • 6.1.3 INCREASE IN PIPELINE PRODUCTS 42
    • 6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 43
  • 6.2 RESTRAINTS 43
    • 6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 43
    • 6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 44
  • 6.3 OPPORTUNITIES 45
    • 6.3.1 INCREASING RESEARCH AND DEVELOPMENT 45
    • 6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 45
    • 6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 46
    • 6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 46
  • 6.4 CHALLENGES 47
    • 6.4.1 LIMITED ACCESS TO TREATMENT 47
    • 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 47

7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 48

  • 7.1 OVERVIEW 49
  • 7.2 DRY AMD 52
  • 7.3 WET AMD 52
    • 7.3.1 MEDICATIONS 53
    • 7.3.2 ANTI-VEGF THERAPY 54
    • 7.3.3 GENE THERAPY 54
    • 7.3.4 SURGERY 54

8 NORTH AMERICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 55

  • 8.1 OVERVIEW 56
  • 8.2 HOSPITALS 59
  • 8.3 SPECIALTY CLINICS 59
  • 8.4 AMBULATORY SURGICAL CENTERS 60
  • 8.5 HOME HEALTHCARE 61
  • 8.6 OTHERS 62

9 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 63

  • 9.1 OVERVIEW 64
  • 9.2 RETAIL SALES 68
    • 9.2.1 HOSPITAL PHARMACIES 69
    • 9.2.2 RETAIL PHARMACIES 69
    • 9.2.3 OTHERS 69
  • 9.3 DIRECT TENDER 69

 

10 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 70

  • 10.1 NORTH AMERICA 71
    • 10.1.1 U.S. 77
    • 10.1.2 CANADA 79
    • 10.1.3 MEXICO 81

11 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 83

  • 11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 83

12 SWOT ANALYSIS 84

13 COMPANY PROFILE 85

  • 13.1 NOVARTIS AG 85
    • 13.1.1 COMPANY SNAPSHOT 85
    • 13.1.2 REVENUE ANALYSIS 85
    • 13.1.3 COMPANY SHARE ANALYSIS 86
    • 13.1.4 PRODUCT PORTFOLIO 86
    • 13.1.5 RECENT DEVELOPMENT 86
      • 13.1.5.1 AGREEMENT 86
  • 13.2 GENENTECH, INC. 87
    • 13.2.1 COMPANY SNAPSHOT 87
    • 13.2.2 COMPANY SHARE ANALYSIS 87
    • 13.2.3 PRODUCT PORTFOLIO 88
    • 13.2.4 RECENT DEVELOPMENT 88
  • 13.3 BAYER AG 89
    • 13.3.1 COMPANY SNAPSHOT 89
    • 13.3.2 REVENUE ANALYSIS 89
    • 13.3.3 COMPANY SHARE ANALYSIS 90
    • 13.3.4 PRODUCT PORTFOLIO 90
    • 13.3.5 RECENT DEVELOPMENT 90
  • 13.4 ADVERUM BIOTECHNOLOGIES, INC. 91
    • 13.4.1 COMPANY SNAPSHOT 91
    • 13.4.2 REVENUE ANALYSIS 91
    • 13.4.3 PRODUCT PORTFOLIO 91
    • 13.4.4 RECENT DEVELOPMENT 92

 

  • 13.5 ASTELLAS PHARMA INC. 93
    • 13.5.1 COMPANY SNAPSHOT 93
    • 13.5.2 REVENUE ANALYSIS 93
    • 13.5.3 PRODUCT PORTFOLIO 94
    • 13.5.4 RECENT DEVELOPMENT 94
  • 13.6 GRAYBUG VISION INC. 95
    • 13.6.1 COMPANY SNAPSHOT 95
    • 13.6.2 REVENUE ANALYSIS 95
    • 13.6.3 PRODUCT PORTFOLIO 95
    • 13.6.4 RECENT DEVELOPMENT 96
  • 13.7 GENSIGHT BIOLOGICS 97
    • 13.7.1 COMPANY SNAPSHOT 97
    • 13.7.2 REVENUE ANALYSIS 97
    • 13.7.3 PRODUCT PORTFOLIO 98
    • 13.7.4 RECENT DEVELOPMENTS 98
      • 13.7.4.1 EVENT 98
      • 13.7.4.2 AWARD 98
  • 13.8 IONIS PHARMACEUTICALS 99
    • 13.8.1 COMPANY SNAPSHOT 99
    • 13.8.2 REVENUE ANALYSIS 99
    • 13.8.3 PRODUCT PORTFOLIO 100
    • 13.8.4 RECENT DEVELOPMENT 100
      • 13.8.4.1 EVENT 100
  • 13.9 IVERIC BIO 101
    • 13.9.1 COMPANY SNAPSHOT 101
    • 13.9.2 PRODUCT PORTFOLIO 101
    • 13.9.3 RECENT DEVELOPMENT 101
  • 13.10 JOHNSON &JOHNSON SERVICES, INC. 102
    • 13.10.1 COMPANY SNAPSHOT 102
    • 13.10.2 REVENUE ANALYSIS 102
    • 13.10.3 PRODUCT PORTFOLIO 103
    • 13.10.4 RECENT DEVELOPMENT 103
      • 13.10.4.1 COLLABORATION 103
  • 13.11 KODIAK SCIENCES INC. 104
    • 13.11.1 COMPANY SNAPSHOT 104
    • 13.11.2 PRODUCT PORTFOLIO 104
    • 13.11.3 RECENT DEVELOPMENT 104

 

  • 13.12 MEIRAGTX LIMITED 105
    • 13.12.1 COMPANY SNAPSHOT 105
    • 13.12.2 PRODUCT PORTFOLIO 105
    • 13.12.3 RECENT DEVELOPMENTS 105
      • 13.12.3.1 EVENTS 105
      • 13.12.3.2 AWARD 106
      • 13.12.3.3 COLLABORATION 106
  • 13.13 OCUGEN INC. 107
    • 13.13.1 COMPANY SNAPSHOT 107
    • 13.13.2 PRODUCT PORTFOLIO 107
    • 13.13.3 RECENT DEVELOPMENTS 107
      • 13.13.3.1 INVESTMENT 107
      • 13.13.3.2 CLINICAL TRIAL 108
  • 13.14 PIXIUM VISION 109
    • 13.14.1 COMPANY SNAPSHOT 109
    • 13.14.2 REVENUE ANALYSIS 109
    • 13.14.3 PRODUCT PORTFOLIO 109
    • 13.14.4 RECENT DEVELOPMENT 110
      • 13.14.4.1 AWARD 110
  • 13.15 REGENXBIO INC. 111
    • 13.15.1 COMPANY SNAPSHOT 111
    • 13.15.2 PRODUCT PORTFOLIO 111
    • 13.15.3 RECENT DEVELOPMENTS 111
      • 13.15.3.1 EVENT 111
      • 13.15.3.2 COLLABORATION 112
      • 13.15.3.3 CERTIFICATION 112

14 QUESTIONNAIRE 113

15 RELATED REPORTS 116